A recent study by Emory University researchers provides new insights into why the mRNA vaccines developed to fight COVID-19 ...

Patients who received the original monovalent mRNA COVID-19 vaccine were less likely than unvaccinated patients to be hospitalized for COVID-19-associated VTE.

Long before mRNA vaccines captured global attention during the COVID-19 pandemic, researchers were already exploring their ...

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

Speculation about the alleged findings of a study on long COVID and post-vaccination syndrome spread widely among vaccine ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

The COVID-19 vaccine confers protection against the development of post-COVID-19 conditions, particularly during the Delta and Omicron eras.

The Covid-19 positivity rate has also seen a rise to 7.1% this past week, versus the 5.5% figure for the past four weeks.

The University of Queensland's BASE facility – within the Australian Institute for Bioengineering and Nanotechnology (AIBN) – and Brisbane-based biotechnology company Vaxxas have been announced as ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Demand for its COVID vaccine has been waning after the pandemic, while adoption of its RSV shot - its second approved product ...